Connect
MJA
MJA

First clinical case of a locally acquired carbapenem-resistant VIM-1 metallo-β-lactamase in Pseudomonas aeruginosa in Australia

John Merlino, Harold W Stokes, Elaine Y-L Cheong and Thomas Gottlieb
Med J Aust 2009; 191 (5): 289.
Published online: 7 September 2009

To the Editor: Nosocomial infections caused by Pseudomonas aeruginosa often prove difficult to treat because of their resistance to multiple drugs. Carbapenems play a pivotal role in the management of severe multidrug-resistant gram-negative Enterobacteriaceae and P. aeruginosa infections. However, reports in Australia of carbapenem resistance due to production of a variety of carbapenemases, including metallo-β-lactamases (MBLs), have been increasing alarmingly.1,2 We wish to report the first clinical case of a VIM-1-producing MBL in Sydney. To our knowledge, this is the first reported locally acquired case of a P. aeruginosa strain producing acquired VIM-1 MBL in Australia.

  • John Merlino1
  • Harold W Stokes2
  • Elaine Y-L Cheong1
  • Thomas Gottlieb1

  • 1 Department of Microbiology and Infectious Diseases, Concord Hospital, Sydney, NSW.
  • 2 Institute for the Biotechnology of Infectious Diseases, Faculty of Science, University of Technology Sydney, Sydney, NSW.

Correspondence: jmerlino@med.usyd.edu.au

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.